CL2018003178A1 - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
CL2018003178A1
CL2018003178A1 CL2018003178A CL2018003178A CL2018003178A1 CL 2018003178 A1 CL2018003178 A1 CL 2018003178A1 CL 2018003178 A CL2018003178 A CL 2018003178A CL 2018003178 A CL2018003178 A CL 2018003178A CL 2018003178 A1 CL2018003178 A1 CL 2018003178A1
Authority
CL
Chile
Prior art keywords
freezing
pharmaceutical compositions
antibody
fragment
drying
Prior art date
Application number
CL2018003178A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
Jan Ivo Massant
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56320265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2018003178A1 publication Critical patent/CL2018003178A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN ANTICUERPO O UN FRAGMENTO DEL MISMO, ADECUADAS PARA EL SECADO POR CONGELACIÓN (ES DECIR LIOFILIZACIÓN). LAS COMPOSICIONES FARMACÉUTICAS, QUE COMPRENDEN UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO DEL MISMO; DE 1 % A 20 % P/V DE SUCROSA; UN AMINOÁCIDO O UNA MEZCLA DE AMINOÁCIDOS; Y UN AGENTE TENSIOACTIVO, SON PROVISTAS COMO COMPOSICIONES FARMACÉUTICAS PARA EL SECADO POR CONGELACIÓN; COMO COMPOSICIONES SECADAS POR CONGELACIÓN (ES DECIR LIOFILIZADAS) QUE SE PUEDEN RECONSTITUIR EN UN DISOLVENTE EN EL MOMENTO DEL USO O COMO FORMULACIONES LÍQUIDAS RECONSTITUIDAS LISTAS PARA SU ADMINISTRACIÓN.
CL2018003178A 2016-05-12 2018-11-08 Composición farmacéutica CL2018003178A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608323.0A GB201608323D0 (en) 2016-05-12 2016-05-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2018003178A1 true CL2018003178A1 (es) 2019-02-01

Family

ID=56320265

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003178A CL2018003178A1 (es) 2016-05-12 2018-11-08 Composición farmacéutica

Country Status (18)

Country Link
US (1) US11407835B2 (es)
EP (1) EP3454899B1 (es)
JP (1) JP7126454B2 (es)
KR (1) KR102436694B1 (es)
CN (1) CN109069643A (es)
AR (1) AR108449A1 (es)
AU (1) AU2017264553A1 (es)
BR (1) BR112018072264A2 (es)
CA (1) CA3022124A1 (es)
CL (1) CL2018003178A1 (es)
CO (1) CO2018011733A2 (es)
EA (1) EA201892446A1 (es)
ES (1) ES2977545T3 (es)
GB (1) GB201608323D0 (es)
IL (1) IL262654A (es)
MX (1) MX2018013215A (es)
SG (1) SG11201809229VA (es)
WO (1) WO2017194646A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
TW202003036A (zh) * 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
AU2021236234A1 (en) * 2020-03-11 2022-10-06 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
BR112022026780A2 (pt) * 2020-06-29 2023-01-17 Hanall Biopharma Co Ltd Formulação para anticorpo anti-fcrn
AU2022274319A1 (en) * 2021-05-12 2024-01-04 Anaptysbio, Inc. Antibody composition
CA3239280A1 (en) 2021-12-01 2023-06-08 UCB Biopharma SRL Formulations comprising fab-peg
CN119233815A (zh) * 2022-05-20 2024-12-31 株式会社大赛璐 液态医药组合物
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CN115708810A (zh) * 2022-11-03 2023-02-24 浙江新码生物医药有限公司 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途
EP4676963A1 (en) * 2023-03-08 2026-01-14 Immunovant Sciences GmbH High concentration protein formulations with polysorbate excipients and methods of making the same
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002324556A1 (en) * 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
CA2764180A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US8788028B2 (en) 2010-07-28 2014-07-22 Medtronic, Inc. Parasympathetic stimulation to enhance tachyarrhythmia detection
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
KR20170065662A (ko) 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
EA201892446A1 (ru) 2019-04-30
JP2019514998A (ja) 2019-06-06
IL262654A (en) 2018-12-31
US11407835B2 (en) 2022-08-09
JP7126454B2 (ja) 2022-08-26
AR108449A1 (es) 2018-08-22
GB201608323D0 (en) 2016-06-29
CN109069643A (zh) 2018-12-21
MX2018013215A (es) 2019-02-21
SG11201809229VA (en) 2018-11-29
WO2017194646A1 (en) 2017-11-16
EP3454899B1 (en) 2024-03-20
CO2018011733A2 (es) 2019-02-08
RU2018141591A3 (es) 2021-01-13
ES2977545T3 (es) 2024-08-26
RU2018141591A (ru) 2020-06-15
EP3454899C0 (en) 2024-03-20
AU2017264553A1 (en) 2018-12-13
EP3454899A1 (en) 2019-03-20
BR112018072264A2 (pt) 2019-02-12
CA3022124A1 (en) 2017-11-16
KR20190008320A (ko) 2019-01-23
KR102436694B1 (ko) 2022-08-25
US20200048346A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CO2018011733A2 (es) Composición farmacéutica
MX383808B (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf.
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2023006541A (es) Formulaciones de dosis fija.
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2025010300A (es) Preparaciones y composiciones de oligosacaridos
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
ECSP19044591A (es) Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
AR102779A1 (es) Composición farmacéutica, su preparación y sus usos
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
AR109798A1 (es) Composición para el tratamiento capilar
MX2021005910A (es) Formulacion de proteina de alta concentracion.
BR112019023074A2 (pt) composição contendo ciclodextrina e bussulfano
CL2017002470A1 (es) Proceso para obtener mezclas de polvo seco
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR125489A2 (es) Composición farmacéutica de antibiótico y método de manufactura
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат